association id |
FEATURE |
Drug id |
Propr |
Public |
Drug Name |
Drug Target |
N FEATURE pos |
N FEATURE neg |
log max Conc tested |
FEATURE neg logIC50 MEAN |
FEATURE pos logIC50 MEAN |
FEATURE deltaMEAN IC50 |
FEATURE IC50 effectSize |
FEATURE neg Glass delta |
FEATURE pos Glass delta |
ANOVA FEATURE pval |
Tissue ANOVA pval |
MSI ANOVA pval |
ANOVA FEATURE FDR % |
a92 |
loss_cnaPANCAN307_(CHD3,GPS2,TP53) |
300 |
1 |
1 |
CX-5461 |
RNA Pol I |
103 |
814 |
2.33 |
2.94 |
3.38 |
0.436 |
0.22 |
0.21 |
0.25 |
7.99e-06 |
3.55e-45 |
2.22e-01 |
1.4 |
a203 |
EWSR1-FLI1_mut |
300 |
1 |
1 |
CX-5461 |
RNA Pol I |
17 |
900 |
2.33 |
3.03 |
0.894 |
-2.14 |
1.1 * |
1.1 * |
1 * |
8.99e-05 |
6.33e-45 |
2.24e-01 |
7.3 |
a209 |
MLL2_mut |
300 |
1 |
1 |
CX-5461 |
RNA Pol I |
96 |
821 |
2.33 |
3.1 |
2.07 |
-1.04 |
0.52 . |
0.52 . |
0.51 . |
9.34e-05 |
6.38e-45 |
2.24e-01 |
7.4 |
a230 |
loss_cnaPANCAN304 |
300 |
1 |
1 |
CX-5461 |
RNA Pol I |
73 |
844 |
2.33 |
2.97 |
3.27 |
0.301 |
0.15 |
0.15 |
0.17 |
1.23e-04 |
6.82e-45 |
2.24e-01 |
8.8 |
a278 |
loss_cnaPANCAN306 |
300 |
1 |
1 |
CX-5461 |
RNA Pol I |
73 |
844 |
2.33 |
2.97 |
3.26 |
0.289 |
0.14 |
0.14 |
0.17 |
1.99e-04 |
7.63e-45 |
2.24e-01 |
12 |
a301 |
loss_cnaPANCAN305 |
300 |
1 |
1 |
CX-5461 |
RNA Pol I |
73 |
844 |
2.33 |
2.97 |
3.24 |
0.269 |
0.13 |
0.13 |
0.16 |
2.44e-04 |
8e-45 |
2.24e-01 |
13 |
a303 |
gain_cnaPANCAN382_(FLT3,WASF3) |
300 |
1 |
1 |
CX-5461 |
RNA Pol I |
20 |
897 |
2.33 |
2.96 |
4.36 |
1.4 |
0.7 . |
0.69 . |
1.4 * |
2.51e-04 |
8.06e-45 |
2.24e-01 |
14 |
a351 |
XRN1_mut |
300 |
1 |
1 |
CX-5461 |
RNA Pol I |
15 |
902 |
2.33 |
3.03 |
0.892 |
-2.14 |
1.1 * |
1.1 * |
1.1 * |
3.5e-04 |
8.71e-45 |
2.24e-01 |
16 |
a365 |
gain_cnaPANCAN363_(ASXL1) |
300 |
1 |
1 |
CX-5461 |
RNA Pol I |
99 |
818 |
2.33 |
2.88 |
3.95 |
1.07 |
0.54 . |
0.53 . |
0.66 . |
3.69e-04 |
8.82e-45 |
2.24e-01 |
17 |